Martha Raymond, Founder and CEO of The Raymond Foundation and Founding Co-Chair and CEO of the GI Cancers Alliance, shared by Jazz Pharmaceuticals , on LinkedIn:
“Jazz Pharmaceuticals , thank you for your partnership, unwavering patient-centered approach and commitment to keeping the patient experience at the heart of your R&D, clinical trials, and therapeutic innovations.”
Quoting Jazz Pharmaceuticals:
“In the gastrointestinal cancer community, scientific progress can represent a beacon of hope for patients and their families.
Hear from Martha Raymond, Founder and CEO of The Raymond Foundation and GI Cancers Alliance, as she shares how advances in treatment pipelines help reassure patients that they are not navigating this journey alone.
At Jazz, we are committed to progressing the science behind treatments for difficult-to-treat GI cancers, like gastroesophageal adenocarcinoma (GEA), to help improve care outcomes.”
You may also be interested in: FDA Approves Ziihera With and Without Tislelizumab Plus Chemotherapy for First-Line HER2-Positive Gastroesophageal Adenocarcinoma
